Boothbay Fund Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-487,000
| Closed | -$6.79M | – | 2585 |
|
|
2022
Q3 | $6.79M | Buy |
487,000
+442,300
| +989% | +$7.12M | 0.17% | 108 |
|
|
2022
Q2 | $617K | Buy |
+44,700
| New | +$716K | 0.02% | 1071 |
|
|
2022
Q1 | – | Sell |
-201,600
| Closed | -$3.28M | – | 2628 |
|
|
2021
Q4 | $3.28M | Buy |
201,600
+161,600
| +404% | +$2.72M | 0.08% | 313 |
|
|
2021
Q3 | $594K | Buy |
+40,000
| New | +$640K | 0.02% | 1009 |
|
|
2021
Q2 | – | Sell |
-115
| Closed | -$265K | – | 2203 |
|
|
2021
Q1 | $265K | Buy |
+115
| New | +$3.21K | 0.01% | 1248 |
|
|
2020
Q3 | – | Sell |
-189
| Closed | -$905K | – | 1286 |
|
|
2020
Q2 | $905K | Buy |
189
+107
| +130% | +$8.27K | 0.06% | 421 |
|
|
2020
Q1 | $516K | Sell |
82
-19
| -19% | -$1.71K | 0.04% | 457 |
|
|
2019
Q4 | $1.25M | Buy |
+101
| New | +$9.04K | 0.11% | 259 |
|
|
2019
Q2 | – | Sell |
-158
| Closed | -$1.77M | – | 940 |
|
|
2019
Q1 | $1.77M | Sell |
158
-107
| -40% | -$11.7K | 0.17% | 136 |
|
|
2018
Q4 | $2.67M | Buy |
265
+128
| +93% | +$13.3K | 0.39% | 51 |
|
|
2018
Q3 | $1.73M | Buy |
137
+53
| +63% | +$5.61K | 0.17% | 115 |
|
|
2018
Q2 | $705K | Buy |
+84
| New | +$6.15K | 0.06% | 253 |
|
|
2016
Q2 | – | Sell |
-3,900
| Closed | -$501K | – | 612 |
|
|
2016
Q1 | $501K | Buy |
+3,900
| New | +$460K | 0.37% | 65 |
|
Boothbay Fund Management's ICPT Position: Q3 2023 in Review
Boothbay Fund Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2023, closing a stake of 941,755 shares — an estimated $10.7M sold.
Boothbay Fund Management first reported a position in ICPT in Q4 2021 and held it in 6 quarters. The position peaked at $10.4M in Q2 2023. 146 funds tracked by Wall St. Rank hold ICPT as of Q3 2023.
- Boothbay Fund Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Boothbay Fund Management sold 941,755 Intercept Pharmaceuticals, Inc. shares in Q3 2023, an estimated $10.7M.
- Boothbay Fund Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2021 and held it in 6 quarters.
- Boothbay Fund Management's Intercept Pharmaceuticals, Inc. position peaked at $10.4M in Q2 2023.
- 146 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2023.
Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.